In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
Food and beverage products containing CBD were introduced in the United States in 2017. Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance. In the United States, numerous products are marketed as containing CBD, but in reality contain little or none. Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the Food and Drug Administration for making unsubstantiated health claims. In February 2019, the New York City Department of Health announced plans to fine restaurants that sell food or drinks containing CBD, beginning in October 2019.
CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere. A 2010 brain cancer study by California scientists found that CBD “enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival.” This means that CBD makes THC even more potent as an anticancer substance. Also in 2010, German researchers reported that CBD stimulates neurogenesis, the growth of new brain cells, in adult mammals.
Representations regarding the efficacy and safety of CBDPure have not been evaluated by the Food and Drug Administration. The FDA only evaluates foods and drugs, not supplements like these products. These products are not intended to diagnose, prevent, treat, or cure any disease. Click here and here to find evidence of a test, analysis, research, or study describing the benefits, performance or efficacy of CBD Oil based on the expertise of relevant professionals.
Given CBD’s reputation as a popular, artisanal remedy, one would think that Epidiolex would command a lot of “off label” attention. After all, physicians often prescribe pharmaceuticals off label to treat conditions that were not the actual focus of clinical trials. But the costly price tag for Epidiolex (more than $30,000 annually) precludes off label prescribing as well as affordable access for tens of millions of Americans without health insurance.
Unfortunately due to strict FDA regulations I am unable to make claims on our products based on your specific needs, I can however say that CBD is a natural anti-inflammatory and could assist. I can also share our top selling products in each category. Please view the links below:http://cbdoilreview.org/product/elixinol-cbd-oil-extract-x-pen-1000mg/http://cbdoilreview.org/product/endoca-hemp-oil-drops-1500mg/http://cbdoilreview.org/product/elixinol-hemp-oil-drops-regular-300mg/http://cbdoilreview.org/product/elixinol-cbd-hemp-oil-capsules-900mg/https://cbdoilreview.org/product/vape-bright-starter-pack-200-mg/This is also a great link to some pages that you may find helpful https://cbdoilreview.org/cbd-cannabidiol/